JonesResearch has revised its rating for Adaptimmune (ADAP, Financial), moving it from a Buy to a Hold. This adjustment reflects ongoing concerns about the company's capital overhang. The firm highlights the need for more transparency regarding Adaptimmune's future financial plans or potential partnerships to address these issues.
The decision to downgrade stems from the anticipation that Adaptimmune might need to establish clearer financial strategies to bolster investor confidence. JonesResearch is closely monitoring the company's next steps in potential strategic moves to ensure sustainable growth and financial stability.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 9 analysts, the average target price for Adaptimmune Therapeutics PLC (ADAP, Financial) is $1.74 with a high estimate of $3.00 and a low estimate of $1.00. The average target implies an upside of 682.23% from the current price of $0.22. More detailed estimate data can be found on the Adaptimmune Therapeutics PLC (ADAP) Forecast page.
Based on the consensus recommendation from 7 brokerage firms, Adaptimmune Therapeutics PLC's (ADAP, Financial) average brokerage recommendation is currently 2.4, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Adaptimmune Therapeutics PLC (ADAP, Financial) in one year is $1.00, suggesting a upside of 349.84% from the current price of $0.2223. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Adaptimmune Therapeutics PLC (ADAP) Summary page.
